ProCE Banner Activity

I-SPY 2.2: Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in High-Risk Stage II-III HER2-Negative Breast Cancer

Conference Coverage
Slideset

In the I-SPY 2.2 trial, neoadjuvant datopotamab deruxtecan plus durvalumab was deemed effective in the immune+ response–predictive subtype in patients with stage II-III breast cancer considered high risk by 70-gene assay, allowing early surgery without chemotherapy. 

Released: June 07, 2024

Expiration: June 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation